Rochester, N.Y.- Nine patients with the Rochester General Health System received injections of a medication that’s the subject of a nationwide recall.
Earlier this week, the FDA issued revised guidelines on a wide range of medications purchased from or produced by the New England Compounding Company after May 21, 2012.
Based on these guidelines Rochester General Health System immediately identified and contacted the nine patients who received one of the company’s injectable medications.
The medication is called 17-hydroxyprogesterone, which is used for the prevention of pre-term labor for high risk patients. The safety of the drug itself has not been called into question by the FDA.
RGHS says patients were contacted because they received the NECC prepared medication at either Rochester General Hospital or Newark-Wayne Community Hospital.
RGHS suspended use of 17-hydroxyprogesterone purchased from NECC on October 4, 2012, when the Food and Drug Administration issued a nationwide order to suspend the use of all medications from the Massachusetts-based company.
